NKTR
New cash, same dilution math
Nektar Therapeutics said it closed its underwritten public offering and walked away with $373.8 million in gross proceeds. The company sold 4.06 million shares of common stock, including the extra 529,891 shares that underwriters gobbled up through their full option exercise.
Why you should care
For a clinical-stage biotech, a fat cash raise can be the difference between keeping the lights on and sending around a very awkward bankruptcy-themed calendar invite. This kind of move usually gives the company more runway to fund trials, operations, and whatever science project is next on the board’s bingo card.
But there’s no free lunch here. More shares in circulation usually means more dilution, so existing investors are paying for that runway with a smaller ownership piece. In biotech, that tradeoff is basically the genre.
The investor takeaway
This isn’t about a drug readout or a regulatory win. It’s about balance-sheet survival and optionality. If Nektar can use the cash to get more clinical milestones in front of investors, the market may tolerate the dilution. If not, the offering just becomes a bigger reminder that early-stage biotech lives and dies by capital access.
Big picture: the company bought itself time. Now it has to turn that time into something more exciting than another share sale.